BMY - UBS cuts BioXcel to neutral; cites regulatory issues financing
2024-02-21 11:03:58 ET
More on BioXcel Therapeutics
- BioXcel Therapeutics announces termination of proposed public offering
- BioXcel stock climbs on FDA fast track designation for prostate cancer therapy
- Seeking Alpha’s Quant Rating on BioXcel Therapeutics
- Historical earnings data for BioXcel Therapeutics
- Financial information for BioXcel Therapeutics